T2 Biosystems, Inc. SEC Filings

Filed On	Filing
10 Jul 2025	25-NSE/A
10 Jul 2025	25-NSE
07 Apr 2025	8-K: Departure/Election of Directors or Officers; Compensation
01 Apr 2025	NT 10-K
20 Feb 2025	8-K: Other Events
14 Feb 2025	8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +1 more
13 Feb 2025	SCHEDULE 13G/A
13 Feb 2025	SCHEDULE 13G/A
11 Feb 2025	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
21 Jan 2025	Proxy statement: special meeting on March 3, 2025
17 Jan 2025	8-K: Entry into a Material Definitive Agreement
08 Jan 2025	PRE 14A
07 Jan 2025	8-K: Results of Operations and Financial Condition; Other Events
03 Jan 2025	8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
02 Jan 2025	Form 4: Liebman Seymour, Director Granted 25,000 Restricted Stock Units
02 Jan 2025	Form 4: Giffin Brett A., Chief Commercial Officer Granted 360,000 Restricted Stock Units
02 Jan 2025	Form 4: Adams Laura Lee, Director Granted 25,000 Restricted Stock Units
02 Jan 2025	Form 4: Cumming John W, Director Granted 35,000 Restricted Stock Units
02 Jan 2025	Form 4: Gibbs Michael Terrence, General Counsel Granted 380,000 Restricted Stock Units
02 Jan 2025	Form 4: Saunders Ninfa, Director Granted 25,000 Restricted Stock Units

Comments